Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.39 |
| ▸ | CACNB4 known ✓ | O00305 | 2/20 | 0.39 |
| ▸ | CACNA1A known ✓ | O00555 | 2/20 | 0.39 |
| ▸ | CACNA1G known ✓ | O43497 | 2/20 | 0.39 |
| ▸ | CACNG3 known ✓ | O60359 | 2/20 | 0.39 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.39 |
| ▸ | CACNA1H known ✓ | O95180 | 2/20 | 0.39 |
| ▸ | CACNB3 known ✓ | P54284 | 2/20 | 0.39 |
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.39 |
| ▸ | CACNG7 known ✓ | P62955 | 2/20 | 0.39 |
| ▸ | CACNA1B known ✓ | Q00975 | 2/20 | 0.39 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.39 |
| ▸ | CACNB1 known ✓ | Q02641 | 2/20 | 0.39 |
| ▸ | CACNG1 known ✓ | Q06432 | 2/20 | 0.39 |
| ▸ | CACNB2 known ✓ | Q08289 | 2/20 | 0.39 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829714 | 0.99 | SLC10A2 (0.52) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8121479 | 0.94 | SLC10A2 (0.51) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7832556 | 0.89 | SLC10A2 (0.39) | SLC10A2ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL8130573 | 0.87 | SLC10A2 (0.49) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8137994 | 0.86 | SLC10A2 (0.41) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8149513 | 0.85 | SLC10A2 (0.45) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8130556 | 0.85 | SLC10A2 (0.47) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL8138537 | 0.84 | SLC10A2 (0.46) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8134365 | 0.84 | SLC10A2 (0.44) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8136885 | 0.84 | SLC10A2 (0.44) | SLC10A2TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0634169-B1 | Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-01-05 | — | — | EP | disclosed |
| US-5948782-A | ANTIINFLAMMATORY AGENT; RHEUMATIC DISEASES | TAKEDA CHEMICAL (JP) | 1999-09-07 | — | — | US | disclosed |
| US-5719157-A | OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0634169-A1 | Pharmaceutical composition containing quinoline or quinazoline derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
| EP-0567107-A1 | Quinoline and quinazoline derivatives for treating arthritis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |